(NASDAQ: TNGX) Tango Therapeutics's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 61.59%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 39.85%.
Tango Therapeutics's earnings in 2026 is -$100,515,000.On average, 12 Wall Street analysts forecast TNGX's earnings for 2026 to be -$172,293,777, with the lowest TNGX earnings forecast at -$200,491,219, and the highest TNGX earnings forecast at -$158,282,542. On average, 8 Wall Street analysts forecast TNGX's earnings for 2027 to be -$192,469,417, with the lowest TNGX earnings forecast at -$238,742,834, and the highest TNGX earnings forecast at -$139,910,461.
In 2028, TNGX is forecast to generate -$160,624,477 in earnings, with the lowest earnings forecast at -$189,939,050 and the highest earnings forecast at -$83,380,982.